Business, energy, technology, markets and global industry news from Business News Today

TROP2

PharmaDeviceNews TROP2
Representative image of antibody-drug conjugate cancer research, illustrating the next-generation ADC platform strategy highlighted by Whitehawk Therapeutics at AACR 2026.
Pharma & Biotech

Avenzo Therapeutics to reveal VBC103 Phase 1 results at ESMO Asia 2026

Avenzo's partner VelaVigo will disclose early human safety and efficacy findings for the Nectin-4/TROP2 antibody-drug conjugate VBC103 at ESMO Asia 2026. The presentation could clarify the clinical potential of dual-antigen targeting, while a separate United States study advances in urothelial cancer.

Read More
Representative image: A cancer patient receives infusion-based oncology care in a modern clinic, reflecting Datroway’s FDA approval as a new first-line treatment option for metastatic triple-negative breast cancer patients who are not eligible for immunotherapy.
Pharma & Biotech

AstraZeneca and Daiichi Sankyo deepen ADC ambitions with Datroway’s TNBC approval

Datroway challenges chemotherapy in first-line TNBC. AstraZeneca and Daiichi Sankyo now face the real test: adoption, safety and access.

Read More
Pharma & Biotech

Why ABION’s ABN202 may be aiming beyond TROP2 antibody-drug conjugate resistance

ABION’s ABN202 showed preclinical promise against TROP2 ADC resistance at AACR 2026. Read what this could mean for solid tumor oncology.

Read More